Health ConditionsThe case definition for low back pain (LBP) used in major epidemiological studies is pain in the posterior aspect of the body from the lower margin of the 12th ribs to the lower gluteal folds, with or without pain referred into one or both lower limbs, and lasting for at least 1 day. This anatomical region corresponds broadly to the lumbar spine and surrounding soft tissues.
Low-back pain is classified as nonspecific or specific as to putative cause, and as acute (lasting less than 6 weeks), subacute (6–12 weeks), or chronic (more than 12 weeks) according to duration of symptoms. Non-specific LBP is pain with no known pathoanatomical cause, whereas LBP with radiculopathy is characterized by leg pain along a specific lumbar nerve root with reflex loss, motor weakness, or sensory loss.
Low back pain is a symptom that cannot be validated by an external standard. It is a disorder with many possible etiologies, occurring in many groups of the population, and with many definitions. In practice, it presents across a wide spectrum — from localized dull or sharp pain, to radiating pain down the leg (sciatica), to stiffness and functional limitation with movement.
Backache is a condition of the musculoskeletal system but intersects with several other physiological systems:
It is estimated that 28% of people experience disabling low back pain sometime during their lives, 14% experience episodes lasting at least 2 weeks, 8% of the entire working population will be disabled in any given year, and the lifetime prevalence of low back pain is 65% to 80%.
In 2017, it was estimated that over 551 million people were affected by low back pain, which was ranked the highest contributor to disability burden worldwide. Neck and back pain ranks fourth among the leading causes of disability-adjusted life years. When considering only years lived with disability (YLDs), neck and back pain ranks 1st among all causes of global YLDs and together with osteoarthritis accounted for 13.6% of YLDs in 2015.
Musculoskeletal disorders caused global economic losses of 2.1 trillion USD in 2021, equivalent to 1.41% of global GDP, with low back pain and other MSDs being the largest contributors to global MSD-related welfare losses.
Most episodes of low back pain will be short-lived and 80% to 90% of attacks resolve in about 6 weeks, irrespective of the administration or type of treatment. However, multiple studies showed recurrent or chronic low back pain, evaluated at 3 months, 6 months, or 12 months, ranging from 35% to 79%.
Risk factors for low back pain are multifactorial, with many possible etiologies. Multiple risk factors include physical factors, social demographic characteristics, habits, and psychosocial factors. An umbrella review included 15 systematic reviews containing 134 cohort studies. Four systematic reviews were of high methodological quality and 11 were of moderate quality. Of the 54 risk factors investigated, 38 risk factors were significantly associated with increased risk of LBP or sciatica in at least one systematic review and the odds ratios ranged from 1.26 to 13.00. Adverse risk factors included characteristics of the individual (e.g., older age), poor general health (e.g., smoking), physical stress on the spine (e.g., vibration), and psychological stress (e.g., depression).
Work exposures to lifting, bending, awkward postures, vibration, and tasks considered physically demanding are associated with an increased risk of developing low back pain; however, independent causal relationships have not been demonstrated. Workplace risk factors for low-back pain include manual lifting and whole-body vibration exposure.
Estimated odds ratios for back pain risk in healthcare workers have been calculated as follows: age 1.23, female gender 1.11, BMI 1.17, lack of regular physical activity 1.56, occupational factors 1.12, patient-related factors 1.24, body position at work 2.55, and stress 1.67.
Obesity, recognized as a chronic and systemic disorder, contributes to the progression of intervertebral disc degeneration and LBP. Research indicates that individuals with obesity have a 1.4 to 1.7 times higher risk of developing chronic LBP. Obesity contributes to LBP through both mechanical stress on the spine and biochemical effects, including systemic inflammation and adipokine-induced extracellular matrix degradation by disc cells.
Key mechanisms include oxidative stress, adipokine signalling, and neuroinflammation that may accelerate spinal degeneration and promote chronic pain. A study noted that 80.6% of the obese population investigated had low back pain, in contrast to their corresponding low-BMI group where the prevalence was less than 60%. Currently, obese and sedentary individuals constitute the most susceptible group to develop low back pain.
Among adults, sedentary lifestyle was a considerable risk factor for LBP (OR=1.24); prolonged sitting time (OR=1.42) and driving time (OR=2.03) were significant risk factors in systematic review and meta-analysis. Sedentary lifestyle was associated with 1.41 times greater risk of developing back pain in one study, and it is a known risk factor for obesity and related disorders.
However, the picture regarding sedentary time and actual LBP development is nuanced. A meta-analysis of longitudinal studies showed that sedentary time of 3–8+ hours per day was not significantly associated with LBP development; however, sedentary time of ≥3 hours per day was associated with poor LBP-related disability (OR 1.24).
Globally, 12.5% of years lived with disability (YLDs) due to low back pain were attributed to smoking. Although smoking has been shown to be associated with the occurrence of low back pain and the development of persistent low back pain, the specific causal mechanisms for these associations remain uncertain. Smoking was associated with LBP with an odds ratio of 1.28 in a systematic review and meta-analysis.
Major depressive disorder and back pain often share common risk factors such as sedentary lifestyle, obesity, and psychosocial stressors. Individuals with depression may be more prone to adopting unhealthy behaviors such as physical inactivity and poor posture, which can contribute to musculoskeletal imbalances and increase the risk of back pain.
Systemic inflammation may act as a mediator for physical inactivity and obesity in the pathogenesis of chronic non-specific low back pain.
There is moderate-quality evidence that a history of back pain is a risk factor for back pain. A previous episode of back pain was a consistent risk factor for a new episode across several studies in a systematic review of 49 articles evaluating more than 150 potential risk factors.
Increased levels of pro-inflammatory mediators in the body can be involved in the pathogenesis of chronic LBP. Adherence to an unhealthy diet pattern, by producing pro-inflammatory mediators, upsets the balance of these mediators in the body. Higher adherence to the Western diet — characterized by higher intake of refined grains, red meat, processed meat, high saturated fat, trans-fatty acids, sweet sugary foods, and caffeine — is associated with the production of high levels of pro-inflammatory cytokines.
A PRISMA-compliant systematic review found that seven out of nine experimental studies reported a pain-relieving effect of dietary changes. Protein, fat, and sugar intake were found to be associated with pain intensity and pain threshold. In conclusion, plant-based diets might have pain-relieving effects on chronic musculoskeletal pain.
Dietary behavioural change in overweight and obese patients is suggested as an important aspect of pain management.
Patients with chronic rheumatoid arthritis pain can show inadequate intake of calcium, folate, zinc, magnesium, and vitamin B6. Chronic pain severity also shows a positive relation with fat and sugar intake in osteoarthritis, and pain threshold shows a positive association with protein intake in fibromyalgia.
A systematic review found efficiency for the following nutritional approaches to chronic musculoskeletal pain: access to dietary counselling (daily recommended protein of at least 1 g per kilogram of body weight); intake of glutamic acid-rich foods such as soy, egg, and cod and tryptophan-rich foods such as milk and peanuts; supplementation of vitamin D and magnesium if lacking; weekly consumption of fish or omega-3 supplements; and availability of botanicals, in particular curcumin and gingerol.
Association evidence: A review study has found that patients with LBP have lower serum 25(OH)D levels, with this association being more common in younger women. One qualitative analysis indicated that vitamin D deficiency is related to increased postoperative pain intensity and a greater propensity to develop chronicity in conditions such as lower back pain, arthrosis, and chemotherapy neuropathy. However, its direct involvement in the transition from acute to chronic pain remains controversial.
Supplementation trials — scientific evidence (mixed/negative overall): A 2024 PRISMA-compliant meta-analysis of ten RCTs found that vitamin D supplementation did not significantly reduce pain scores compared to control groups (SMD: −0.130, 95%CI=−0.260 to 0.000; I²=0%), regardless of participants' baseline vitamin D levels. Long-term supplementation showed no notable improvement in chronic LBP outcomes.
An earlier systematic review and meta-analysis concluded that vitamin D supplementation is not more effective than placebo, no intervention, or other conservative/pharmacological interventions for LBP (based on very low-quality evidence). These results were consistent regardless of the type of LBP or type of vitamin D supplementation. Until well-designed and adequately powered clinical trials suggest otherwise, the prescription of vitamin D for LBP cannot be recommended.
A 2017 systematic review concluded that there is an inconsistent association between vitamin D deficiency and LBP. Another systematic review of clinical trials indicated that vitamin D supplementation was not more effective than placebo in LBP. However, one quasi-experimental clinical trial found that supplementation of vitamin D along with physiotherapy provides better efficacy compared to physiotherapy alone when managing LBP.
A systematic review concluded that among generally healthy older adults with adequate vitamin D levels who were not specifically selected for vitamin D deficiency, low bone mass, or osteoporosis, daily supplementation with 2,000 IU of vitamin D did not provide any musculoskeletal health benefits.
Evidence summary: The overall body of RCT evidence (as of 2024) does not support routine vitamin D supplementation as a standalone treatment for back pain, regardless of baseline vitamin D status. Evidence is rated as very low to low quality. The association between deficiency and pain chronicity is biologically plausible but not yet causally established in well-controlled human trials.
Patients with chronic rheumatoid arthritis pain can show inadequate intake of magnesium alongside calcium, folate, zinc, and vitamin B6. Supplementation of magnesium, if lacking, was identified among nutritional strategies reviewed for chronic musculoskeletal pain management. Magnesium plays roles in neuromuscular transmission and muscle contraction, making it physiologically relevant to musculoskeletal pain conditions. Clinical trial evidence specifically isolating magnesium supplementation for back pain in isolation is limited, and the evidence base noted in systematic reviews of musculoskeletal nutrition draws largely on observational and cross-sectional data.
Scientific evidence: A 2007 meta-analysis of inflammatory joint pain studies found that omega-3 supplementation (usually fish oil) was associated with significant reductions in joint pain intensity, minutes of morning stiffness, number of painful or tender joints, and nonsteroidal anti-inflammatory drug use.
Previous observational studies suggested an important role of omega-3 in low back pain. A two-sample Mendelian randomization study was conducted to identify the putative causal link between omega-3 and low back pain. The study found that as plasma omega-3 levels genetically increased, the risk of low back pain showed a decreased trend, though results did not reach conventional statistical significance (MR-Egger Beta = −0.593, p = 0.228).
An integrative review of clinical trials observed a reduction in musculoskeletal pain with different types of nutritional interventions including fish oil (omega-3). Pain-relieving effects of omega-3 polyunsaturated fatty acid supplementation have been reported in patients with lower back pain and rheumatoid arthritis.
Evidence summary: Omega-3 fatty acids show the most consistent mechanistic rationale (anti-inflammatory prostaglandin modulation) and positive signal in observational and some interventional data for musculoskeletal pain broadly. However, direct, large RCT evidence specifically for LBP is limited. Evidence for inflammatory joint pain is moderate. Effect on pure back pain remains preliminary.
Calcium is essential for bone mineral density and vertebral structural integrity. Patients with chronic rheumatoid arthritis pain can show inadequate intake of calcium alongside other micronutrients, and patients with chronic fibromyalgia pain show a lower intake of calcium compared to healthy individuals. While calcium deficiency is clinically associated with conditions such as osteoporosis that predispose to vertebral fractures and related back pain, direct evidence for calcium supplementation reducing non-specific back pain in otherwise healthy individuals is not established in the reviewed literature.
Traditional use: Devil's claw is a plant native to southern Africa, where the dried secondary roots have been used in traditional medicine for centuries by indigenous peoples for pain relief, fever, and digestive complaints. The active constituents are iridoid glycosides, principally harpagoside.
Scientific evidence (strongest herbal evidence for LBP): The 2014 Cochrane Review on herbal medicine for low-back pain, which included 14 trials (2050 participants), found that daily doses of Devil's Claw standardized to 50 mg or 100 mg harpagoside may be better than placebo for short-term improvements in pain and reduced use of rescue medication (two trials, 315 participants, low-quality evidence). Another trial demonstrated relative equivalence to 12.5 mg per day of rofecoxib (Vioxx®) (one trial, 88 participants, very low-quality evidence).
The NCCIH references this 2014 Cochrane review of two clinical trials involving 315 participants, which found low-quality evidence that daily doses of devil's claw may be better than placebo for short-term improvements in low-back pain and may reduce use of rescue medication. A 2008 review of dietary supplements for osteoarthritis concluded that there is insufficient reliable evidence of long-term safety or effectiveness of devil's claw for this condition.
Evidence summary: Low-quality evidence supports short-term pain reduction for LBP. Longer-term safety and efficacy remain unestablished. The Cochrane-rated evidence is among the strongest of any herbal preparation for back pain specifically, though absolute quality remains low.
Traditional use: Willow bark has been used for pain and fever in European and Asian traditional medicine for thousands of years. The bark of several Salix species was the historical source from which salicin and ultimately salicylic acid were chemically isolated, leading to the development of aspirin. Traditional preparations included decoctions and teas of the dried bark, and the plant was referenced in ancient Egyptian, Greek, and Chinese medical traditions.
Scientific evidence: The 2014 Cochrane Review found that daily doses of white willow bark standardized to 120 mg or 240 mg salicin are probably better than placebo for short-term improvements in pain and rescue medication (two trials, 261 participants, moderate-quality evidence). A standardized daily dose of 240 mg salicin reduced pain about the same as a daily dose of 12.5 mg of Vioxx® (a non-steroidal anti-inflammatory drug).
There is no evidence yet that any of these herbal substances are safe and useful for long-term use.
Evidence summary: Moderate-quality evidence for short-term LBP pain relief at standardized salicin doses of 120–240 mg/day. Rated above devil's claw by some reviewers on methodological grounds. Long-term safety is unestablished. Note: individuals with salicylate sensitivity or on anticoagulants require consideration, though this article does not serve as medical guidance.
Traditional use: Capsicum preparations have been used topically in traditional Mesoamerican and Asian medicine for pain, applying hot pepper preparations to the skin to produce counter-irritation and local warming effects. Capsaicin, the principal pungent alkaloid, acts on TRPV1 receptors in sensory neurons.
Scientific evidence: The Cochrane Review found that capsicum frutescens (cayenne) reduces pain more than placebo. Based on current evidence, it is not clear whether topical capsicum cream is more beneficial for treating people with acute LBP compared to placebo (one trial, 40 participants, low-quality evidence).
Evidence summary: Very limited RCT evidence for topical use in LBP; evidence rated as low quality and based on a single small trial. Physiological mechanism via TRPV1 desensitization is reasonably well established in pain neuroscience but has not yet been confirmed in adequately powered back pain RCTs.
Traditional use: Comfrey has a centuries-old tradition as a medicinal plant. Today, multiple randomized controlled trials have demonstrated the efficacy and safety of comfrey preparations for the topical treatment of pain, inflammation, and swelling of muscles and joints in degenerative arthritis, acute myalgia in the back, sprains, contusions, and strains after sports injuries and accidents.
Scientific evidence: A randomized controlled trial showed a significant treatment difference between comfrey root extract and placebo for back pain. The pain intensity on active standardized movement decreased approximately 95.2% in the comfrey extract group compared to 37.8% in the placebo group (p < 0.001). The Cochrane review also noted that comfrey (Symphytum officinale L.) seems to reduce pain more than placebo, though evidence was of moderate quality at best.
ESCOP states that comfrey root has also been used for tendinitis syndrome, knee joint injuries, and non-active gonarthrosis, although published scientific evidence does not yet adequately support these indications.
Evidence summary: Topical comfrey root extract has the most convincing single-trial data for acute back myalgia, with statistically significant and clinically notable pain reduction. However, evidence quality remains moderate, and internal use is not appropriate due to known pyrrolizidine alkaloid content associated with liver toxicity. ESCOP and regulatory bodies restrict comfrey to topical use only.
Traditional use: Turmeric has been used for thousands of years in Ayurvedic and traditional Chinese medicine for inflammatory conditions, joint pain, digestive complaints, and as a culinary spice. In Ayurveda, it was incorporated into pastes, decoctions, and ghee-based preparations for musculoskeletal pain and swelling.
Scientific evidence: Preliminary findings from laboratory research suggest that curcumin, a chemical found in turmeric, may have anti-inflammatory properties; but in spite of its long history of use for inflammatory disorders, there is insufficient evidence to support the use of turmeric supplementation for these disorders according to NCCIH.
It is challenging to compare the available evidence on turmeric, as oral curcumin products vary in how much curcumin they actually contain and often contain substances from other plants such as piperine from black pepper. Combining curcumin with piperine is one way to improve bioavailability. Several meta-analyses have evaluated oral turmeric or curcumin for osteoarthritis measures related to relieving knee pain and stiffness, increasing joint strength, improving joint mobility, and other functions. The initial evidence is positive; higher-quality evidence is needed to reach definitive conclusions, and more research is needed to understand the impact of bioavailability on curcumin's effects.
Evidence for curcumin and back pain specifically (rather than joint pain generally) is largely indirect, drawn from its general anti-inflammatory properties and arthritis trials. One randomized, double-blind, placebo-controlled, three-arm study (N=94) found that a Boswellia serrata extract co-delivered with curcumin for 28 days significantly reduced pain, stiffness, and neck-related disability, with significant anti-inflammatory effects.
Evidence summary: Curcumin has strong in vitro and animal mechanistic evidence for anti-inflammatory action. Clinical evidence for osteoarthritis joint pain is moderately positive but rated as needing higher-quality trials. Evidence specific to low back pain is preliminary and largely from combination-product studies. Bioavailability is a significant limiting factor; enhanced-absorption formulations (with piperine or phospholipid complexes) are used in most positive clinical trials.
Traditional use: Boswellia (Indian frankincense) has been used for centuries in Ayurvedic medicine for inflammatory and musculoskeletal conditions. The gum-resin obtained from the bark is the medicinal part, historically used internally and topically for arthritis, lower back pain, and other inflammatory complaints.
Scientific evidence: A 2014 Cochrane review concluded that the Ayurvedic herb Boswellia serrata, taken orally, may have modest benefits for osteoarthritis symptoms; however, the overall evidence is weak. Formulations containing boswellia extracts have been used in the management of osteoarthritis, rheumatoid arthritis, Crohn's disease, and collagenous colitis. Dozens of preparations are commercially available. Several studies have found boswellia extracts to have a favorable and acceptable safety profile; minor adverse effects include diarrhea, abdominal pain, and nausea.
Nutraceuticals including boswellia serrata extracts yield varying degrees of effectiveness in the context of joint disorders, alongside glucosamine, chondroitin, collagen, and MSM.
Evidence summary: Boswellia shows preliminary positive evidence for osteoarthritis and some musculoskeletal inflammatory conditions, but direct high-quality RCT evidence for non-specific low back pain is limited. Evidence is rated weak to moderate overall. Combination products with curcumin show early promise for spinal pain, but study numbers and sizes remain limited.
Traditional use: Historically, ginger has been used in Asian medicine to treat stomach aches, nausea, and diarrhea. Today, ginger is used as a folk or traditional remedy for postsurgery nausea; nausea caused by motion, chemotherapy, and pregnancy; rheumatoid arthritis; osteoarthritis; and joint and muscle pain.
Scientific evidence: Ginger has a pain-reducing effect and can modulate pain through various mechanisms including inhibition of prostaglandins via the COX and LOX pathways, antioxidant activity, inhibition of the transcription factor NF-κB, or acting as an agonist of vanilloid nociceptors. A narrative review summarized the last ten years of RCTs in which ginger was used as a pain reliever for dysmenorrhea, delayed onset muscle soreness, osteoarthritis, chronic low back pain, and migraine.
Based on available evidence, it is unclear whether supplementation of ginger is beneficial in treating rheumatoid arthritis, osteoarthritis, or joint and muscle pain according to NCCIH. A 2020 systematic review and meta-analysis of seven trials found insufficient evidence to support the use of oral ginger compared with placebo in pain relief and function improvement in patients with knee osteoarthritis.
Current evidence in vitro and in animal models demonstrates that many different compounds of ginger possess antioxidative and anti-inflammatory activities that may be active in lowering chronic inflammatory disease symptoms, in particular pain. However, human studies assessing whether oral or topical ginger has a positive effect by reducing pain are not numerous, and in these studies different dosages, methods of administration, product formulations, and study designs were used.
Evidence summary: Ginger's mechanism of action is pharmacologically plausible. Evidence in human RCTs for musculoskeletal and back pain is insufficient and inconsistent. Animal and in vitro data are promising. Clinical evidence is preliminary.
An integrative review of 17 clinical trials observed a reduction of musculoskeletal pain with different types of nutritional interventions, such as vegan and Mediterranean diets and the consumption of blueberry, strawberry, passion fruit peel extract, argan oil, fish oil (omega-3), olive oil, and undenatured type II collagen and vitamin D gel capsules. Eight studies evaluated the profiles of inflammatory markers, and decreased interleukin (IL)-6, IL-1β, and tumor necrosis factor-α levels were observed in two studies.
Several foods are considered potentially beneficial for reducing musculoskeletal pain including fruits, vegetables, and whole grains. Foods with functional properties that have been studied for anti-inflammatory effects include omega-3 present in fish oil, olive oil, turmeric, and green tea; resveratrol in grapes and wine; capsaicin in pepper; and various flavonoids in cabbage, cocoa, apples, and citrus fruits.
Globally, 11.5% of YLDs due to low back pain were attributed to elevated BMI. Although obesity has been shown to be associated with the occurrence of low back pain and the development of persistent low back pain, the specific causal mechanisms for these associations remain uncertain. The clinical implication is that weight reduction through dietary change is a relevant target in overweight individuals with back pain, though this is primarily through biomechanical and systemic inflammatory load reduction rather than through any single nutrient.
Body position at work, stress, and lack of physical activity were the strongest risk factors for LBP in a systematic review and meta-analysis in healthcare workers, with physical activity having an OR of 1.56. Regular physical activity, including core muscle strengthening and aerobic exercise, is supported in the reviewed literature as a preventive and adjunct management strategy for LBP, through both biomechanical and systemic anti-inflammatory effects.
Mendelian randomization studies have examined insomnia as a lifestyle factor in the context of back pain alongside BMI, smoking, alcohol consumption, and leisure sedentary behavior. Insomnia has been identified as a variable of interest in the causal pathway to back pain in this methodological framework, though causal directionality remains an active area of investigation.
Beyond ergonomic factors, sociodemographic characteristics, and modifiable lifestyle behaviors, smoking significantly contributes to the prevalence of LBP globally. Smoking is consistently identified across systematic reviews as a modifiable risk factor, with proposed mechanisms including impaired disc nutrition through microvascular effects and systemic pro-inflammatory signaling.
The 2021 PMC clinical review identified low back pain and musculoskeletal pain as conditions studied in arnica clinical trials, and the German Commission E has approved topical arnica for rheumatic muscle pain. Topical arnica gel has been tested as an adjunct for musculoskeletal pain including the back, with some positive outcomes noted in trial summaries.
Oral ATP disodium has been studied in a randomized, double-blind, placebo-controlled trial specifically for subacute low back pain. Additionally, ATP capsules are registered in France for low back pain of muscular origin. The mechanism likely involves ATP's role as a local regulator of inflammation and nociception via purinergic receptors. Evidence remains limited to a small number of trials.
Boswellia serrata, the Indian frankincense tree, has substantial clinical evidence for musculoskeletal pain including low back pain. A 2020 systematic review and meta-analysis (7 RCTs, 545 patients) found Boswellia significantly reduced pain and improved joint function versus controls. A randomized, double-blind, placebo-controlled trial confirmed efficacy of a Boswellia-turmeric combination for chronic low back pain over 90 days.
Boswellic acids are the active pentacyclic triterpene acids in Boswellia serrata extracts. They selectively inhibit 5-lipoxygenase (5-LOX), reducing leukotriene production and NF-κB-mediated inflammation. Clinical RCTs and meta-analyses have documented their efficacy in reducing musculoskeletal pain, with specific trials demonstrating benefit in chronic low back pain.
Medical News Today cites a 2016 study showing camphor oil relieved lower back pain. Camphor is a common ingredient in OTC topical analgesics indicated for minor backache. Its analgesic mechanism involves TRPV1 desensitization and TRPA1 inhibition in sensory nerves.
Capsaicin, the active vanilloid alkaloid of capsicum, is supported by multiple RCTs for topical treatment of chronic nonspecific low back pain. It acts via TRPV1 receptor activation, depleting substance P from nociceptors to produce lasting desensitization. Double-blind trials with capsaicin plasters or creams showed statistically significant pain reduction versus placebo (p=0.002) in populations with chronic LBP.
Topical capsicum (Capsicum frutescens) preparations are supported by multiple RCTs and two Cochrane reviews for nonspecific chronic low back pain. A double-blind, placebo-controlled trial (n=154) found a capsicum plaster containing 11 mg capsaicinoids reduced pain by 42% versus 31% for placebo (p=0.002) over 3 weeks. Capsaicin depletes substance P from nociceptive C-fibers, producing reversible desensitization to pain.
Topical cayenne pepper cataplasms and capsaicin creams have been used in traditional medicine and evaluated in controlled studies for back pain. A PMC study specifically used cayenne pepper cataplasm for back pain and rheumatism. Capsaicin cream is used clinically for lower back pain via the same substance P depletion mechanism as other musculoskeletal pain.
Chondroitin sulfate, a structural glycosaminoglycan of articular cartilage and intervertebral disc, has been studied for low back pain associated with degenerative disc disease and spinal osteoarthritis. A 2022 meta-analysis (8 RCTs, 3,793 patients) found glucosamine-chondroitin combination significantly improved WOMAC scores versus placebo. Clinical evidence supports its use in chronic back pain related to disc and facet joint degeneration.
Spinal intervertebral discs are composed primarily of type I and type II collagen, and degenerative disc disease involves progressive collagen breakdown in the annulus fibrosus and nucleus pulposus. A randomized, double-blind, placebo-controlled trial found collagen peptide ingestion significantly improved functional limitations associated with lower back discomfort. Evidence is early-stage but mechanistically plausible and supported by at least one RCT.
Multiple randomised controlled trials demonstrate topical comfrey root extract significantly reduces acute upper and lower back pain versus placebo. A multicentre, double-blind, three-arm RCT (n=379) found a 35% comfrey root extract plus methyl nicotinate combination markedly superior to placebo on pain VAS during movement. The German Commission E and ESCOP monographs list low back pain among substantiated indications for topical comfrey root preparations.
Curcumin, the primary bioactive curcuminoid of turmeric, has documented efficacy in managing low back pain and musculoskeletal inflammation in RCTs. It inhibits COX-2, NF-κB, and 5-LOX pathways. Double-blind RCTs including a 90-day trial in chronic LBP patients (n=90) showed significant reductions in pain, disability, and inflammatory biomarkers versus placebo.
Curcuminoids—the collective mixture of curcumin, desmethoxycurcumin, and bis-desmethoxycurcumin from turmeric—underlie the anti-inflammatory effects demonstrated in RCTs for low back pain. Double-blind placebo-controlled trials using curcuminoid-standardized extracts show significant reductions in LBP pain scores, disability indices, and serum inflammatory biomarkers versus placebo.
Devil's Claw (Harpagophytum procumbens) is one of the best-studied herbal remedies for low back pain. The 2006 and 2014 Cochrane reviews found strong to moderate evidence that daily doses standardized to 50–100 mg harpagoside significantly reduced pain versus placebo. One high-quality RCT demonstrated equivalence to 12.5 mg/day rofecoxib for acute non-specific low back pain. Its active iridoid glycoside harpagoside inhibits NF-κB, COX-2, and iNOS inflammatory pathways.
DHA (docosahexaenoic acid), a long-chain omega-3 fatty acid, contributes to LBP reduction as part of fish oil supplementation in multiple RCTs. DHA serves as a precursor to D-series resolvins that resolve inflammation and is involved in attenuating IVD degeneration. An RCT of 36 women supplemented with fish oil (550 mg EPA + 205 mg DHA daily for 3 months) found marked reductions in low back pain.
EPA (eicosapentaenoic acid) has specific RCT evidence for pain relief in adults with lower back pain, as reported in a Mendelian randomization review (Frontiers in Nutrition 2022). EPA attenuates IVD degeneration by inducing autophagy and reducing endoplasmic reticulum stress in nucleus pulposus cells. It also reduces prostaglandin E2 synthesis and inflammatory cytokine production relevant to LBP pathophysiology.
Fish oil, as the primary dietary source of EPA and DHA, has RCT evidence for reducing low back pain. A 3-month RCT (n=36; 15 mL fish oil daily) found marked LBP reduction. A clinical trial (NCT02774109) studied 3000 mg/day fish oil with EPA and DHA for 8 weeks in chronic nonspecific LBP, and a 2006 Surgical Neurology study found reduced pain and NSAID use in neck/back pain patients after fish oil supplementation.
Ginger (Zingiber officinale) has been studied in RCTs for chronic low back pain, with a PMC narrative review of the last decade's RCTs confirming clinical use for dysmenorrhea, muscle soreness, osteoarthritis, and chronic LBP. Its mechanism involves inhibition of prostaglandin synthesis via COX and LOX pathways. A clinical trial involving aromatic ginger oil found efficacy in chronic LBP, and multiple studies show anti-inflammatory effects.
Glucosamine, a naturally occurring amino monosaccharide in cartilage, has been studied for spinal and joint pain including low back pain associated with disc degeneration and osteoarthritis. A study in Osteoarthritis and Cartilage found glucosamine and chondroitin can reduce pain and improve mobility in chronic back pain with degenerative disc disease. Mechanistically, glucosamine provides proteoglycan synthesis precursors for nucleus pulposus and articular cartilage.
Harpagoside is the primary active iridoid glycoside constituent of Devil's Claw standardized for clinical use in low back pain. The Cochrane review identified it as the standardization marker used in RCTs demonstrating pain reduction greater than placebo at daily doses of 50–100 mg. It inhibits NF-κB, COX-2, and iNOS signaling pathways associated with musculoskeletal inflammation.
Intervertebral disc (IVD) degeneration is a leading cause of low back pain, and HA is a natural component of the disc extracellular matrix. Intradiscal HA injection has been explored in early-phase human trials and preclinical models. High-molecular-weight HA has shown anti-inflammatory and analgesic properties in IVD models, though robust randomized controlled trials in humans remain limited. Oral HA for low back pain has only one identified clinical study to date.
Topical menthol products are used clinically for back pain relief, with counterirritant properties and sodium channel blockade providing temporary analgesia. Clinical evidence is derived from trials of menthol in musculoskeletal pain broadly, including back pain.
MSM (methylsulfonylmethane) has been studied in clinical trials for musculoskeletal pain, including osteoarthritis and specifically low back pain. A randomized double-blind placebo-controlled safety and efficacy trial (6 g/day MSM for 16 weeks) in LBP and osteoarthritis patients documented analgesic and anti-inflammatory effects. MSM combined with boswellic acids showed efficacy comparable to glucosamine sulfate for knee arthritis in a 120-patient RCT.
Omega-3 fatty acids (EPA and DHA) have multiple RCTs and a Mendelian randomization study (n=79,452) supporting their role in reducing low back pain. EPA and DHA attenuate intervertebral disc degeneration, reduce inflammatory cytokine production, and serve as precursors to pro-resolving mediators. A 2006 Surgical Neurology study found reduced pain and NSAID use in nonsurgical neck/back pain patients after fish oil supplementation.
Salicin (as standardized willow bark extract) has the strongest clinical evidence base of any condition studied. Multiple RCTs and a Cochrane review support its use for short-term relief of nonspecific low back pain, with a clear dose-response effect. The 240 mg/day salicin dose outperforms placebo significantly and performs comparably to rofecoxib (COX-2 inhibitor).
Serratiopeptidase is clinically indicated and prescribed for back pain in India, and is listed across multiple clinical references as an indicated condition. However, the Bhagat 2013 systematic review noted no dedicated studies on back pain were found, and the Wikipedia assessment confirms no randomized evidence specifically for back pain exists. Use is based on extrapolation from its anti-inflammatory/analgesic properties.
Turmeric (Curcuma longa) and its active curcuminoid fraction have been studied in RCTs for low back pain, including a double-blind placebo-controlled trial showing significant superiority of a turmeric-Boswellia formulation over placebo for acute LBP (p<0.001 for pain at rest, movement, and pressure pain). Curcumin inhibits COX-2, iNOS, NF-κB, and LOX pathways involved in spinal inflammation.
Vitamin D deficiency is consistently and significantly associated with increased low back pain severity, paraspinal muscle atrophy, and lumbar disc degeneration. A retrospective study (n=232 postmenopausal women) found severe deficiency correlated with higher VAS pain scores (p=0.002) and more severe disc degeneration at multiple lumbar levels. Mechanistically, vitamin D inhibits NF-κB and ferroptosis in nucleus pulposus cells and supports musculoskeletal function.
Vitamin D3 (cholecalciferol) is the biologically preferred form of vitamin D for supplementation in back pain. A randomized placebo-controlled trial studied 300,000 IU intramuscular vitamin D3 for discogenic pain in lumbar disc herniation. A comparative clinical trial found vitamin D3 supplementation significantly reduced VAS pain and IL-6 in adults with LBP versus untreated control, comparable to ginger extract.
White willow bark (Salix alba), containing salicin as its principal active compound, has moderate Cochrane-level evidence for short-term improvement in chronic low back pain. Two moderate-quality RCTs involving 261 participants found daily doses of 120–240 mg salicin superior to placebo for pain and rescue medication use. A dose of 240 mg salicin daily was comparable in efficacy to 12.5 mg/day rofecoxib.
Willow bark has the strongest clinical evidence for low back pain among all its indicated uses. A landmark RCT (Chrubasik et al., Am J Med 2000, n=191) showed a dose-dependent analgesic effect, with 39% of the high-dose group (240 mg salicin/day) pain-free in the final week vs. 6% on placebo. A systematic review confirmed moderate evidence of effectiveness, finding its analgesic effect not inferior to rofecoxib. The EMA and ESCOP both formally recognize willow bark dry extract for short-term treatment of low back pain.
Wintergreen's active constituent, methyl salicylate, is FDA-recognized as a topical counterirritant and analgesic indicated for simple backache. A large real-world Phase IV trial (n=3,515) found compound methyl salicylate liniment significantly reduced soft tissue pain including in the back (mean VAS 5.34 vs 2.79, p<0.0001). Evidence for wintergreen oil alone—distinct from methyl salicylate preparations—is limited, with no dedicated RCTs on wintergreen oil as an isolate.
Epimedium has a classical TCM indication for soreness and weakness of the back and knees, attributed to kidney yang deficiency. The Compendium of Materia Medica records its use to nourish essence, strengthen tendons and bones, and tonify the waist and knees. No clinical trials specifically targeting backache as a primary endpoint have been conducted.
In Traditional Chinese Medicine (TCM), dodder seed (Tu Si Zi) is a classic remedy for lower back pain attributed to kidney-yang deficiency. TCM materia medica texts describe it as treating 'aching and weakness of the loins and knees.' European folk traditions also used dodder as an analgesic for back and joint pain. No controlled human clinical trials isolating dodder for backache have been published.
Lower back pain (lumbago) is the primary classical indication for eucommia bark in TCM, documented in the Shennong Herbal Classic and the Chinese Pharmacopoeia. It is attributed to 'kidney yang deficiency' in TCM theory. No placebo-controlled human RCTs specifically for backache have been identified.
In TCM, Gentiana macrophylla is used for wind-damp musculoskeletal pain including back pain, scapulohumeral periarthritis, and lumbar complaints. The Phytomedicine review of Radix Gentianae Macrophyllae documents its traditional indication for 'scapulohumeral periarthritis' alongside arthritis and stroke. Its anti-inflammatory and analgesic properties provide pharmacological plausibility.
Gravel root has a documented traditional use for backache, particularly when the pain is attributed to renal or urinary causes such as kidney stones or bladder irritation. Herbalists have included it in formulas targeting kidney-related back pain. No clinical trials have assessed this use specifically.
Traditional Chinese medicine uses Impatiens stems and roots specifically for lumbago (lower back pain) and neuralgia. This use is documented in multiple ethnobotanical reviews and supported by the plant's general antinociceptive pharmacology, though no clinical studies exist.
Common milkweed (Asclepias syriaca) was used by multiple Indigenous peoples of North America to treat backache and lumbago. This use is documented in ethnobotanical records from tribes such as those of the mid-Atlantic and Midwest. A 19th-century medical journal entry from 1888 specifically references A. syriaca for lumbago. No clinical trials have investigated this indication.
Ethnobotanical records document that the Kawaiisu people of North America used a decoction of Mimulus guttatus stems and leaves as a herbal steam bath for chest and back soreness. This is a physical folk medicine use distinct from the Bach flower remedy tradition. No clinical or preclinical research has examined this application.
Mustard plasters are traditionally applied to the back for relief of backache and muscle pain, exploiting the rubefacient and counterirritant properties of AITC. This is a well-documented folk remedy with a long history in Western and South Asian medicine, though no controlled human trials exist specifically for backache.
Lower back soreness and weakness is a well-documented traditional TCM indication for Ligustrum lucidum, associated with liver-kidney yin deficiency. The 2020 Chinese Pharmacopoeia includes 'invigorating muscles and bones' among its functions. No clinical trial evidence exists for this specific indication.
The EMA's HMPC Committee recognizes queen of the meadow as a traditional herbal medicinal product for the relief of minor joint pain including lower back pain. This recognition is based on documented traditional use, not clinical trial evidence. The salicylate content of the plant provides a plausible analgesic mechanism.
Rose hip has documented traditional use for back pain in European herbal medicine, listed by RxList and Restorative Medicine's monograph as a traditional application for back and leg pain. The anti-inflammatory mechanisms documented in rose hip for joint conditions (COX inhibition, cytokine reduction) provide pharmacological plausibility for this traditional use.
Solomon's seal is documented in TCM, Ayurvedic, and Western herbal traditions for back pain relief, attributed to its connective-tissue tonifying and anti-inflammatory actions on vertebral tendons, ligaments, and spinal discs. Drugs.com (citing Zhao 2018) lists backache as a traditional indication across multiple Polygonatum traditions.
Traditional use of spruce bark steam baths and resin plasters for backache and lumbago is documented in Native North American and European ethnobotanical records. Alaskan traditional medicine describes spreading pitch on canvas and applying it to a sore back. Spruce needle oil in bath and topical application is also noted for musculoskeletal pain including the back.
Teasel root (Dipsacus asper, known as Xu Duan in TCM) has a long-standing traditional use for lower back pain, particularly pain associated with kidney and liver deficiency in the TCM framework. It is traditionally used to strengthen the lower back and knees and fortify bones and sinews. No controlled human clinical trials have been conducted specifically for this indication.
Lumbago (lower back pain) is consistently listed across multiple TCM monographs, ethnomedicinal surveys, and pharmacopeial formulas as an indication for X. strumarium. The plant's analgesic and anti-inflammatory properties support this use mechanistically. No clinical studies targeting lumbago specifically have been published.
Go back